查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924736

狂犬病免疫球蛋白市场按类型、给药途径、分销管道和最终用户划分 - 全球预测（2026-2032 年）

Rabies Immunoglobulins Market by Type, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年狂犬病免疫球蛋白市场价值为 8.0215 亿美元，预计到 2026 年将成长至 8.562 亿美元，年复合成长率为 8.11%，到 2032 年将达到 13.8547 亿美元。

主要市场统计数据
基准年 2025 8.0215亿美元
预计年份：2026年 8.562亿美元
预测年份：2032年 13.8547亿美元
复合年增长率 (%) 8.11%

在现代医疗保健服务中，确定狂犬病免疫球蛋白获取的临床和运营背景、供应链优先事项以及相关人员的需求

狂犬病是一项至关重要的公共卫生优先事项，及时注射免疫球蛋白可以挽救生命。围绕这些治疗的格局受到临床紧迫性、不断发展的生产模式和监管监督的共同影响。本导言阐述了狂犬病免疫球蛋白在暴露后预防中的临床作用，并概述了相关人员必须关注的关键供应链、生产和临床应用趋势。此外，本导言也重点介绍了影响患者获得治疗的临床实践模式和分销管道之间的相互作用。

生产製造创新、采购流程现代化和监管重点如何重塑狂犬病免疫球蛋白的供应、永续性和临床实践？

由于生物製造技术的进步、医疗系统采购方式的改变以及人们对公平获取的期望日益提高，狂犬病免疫球蛋白市场正在经历变革性变化。在生产方面，对更具可扩展性和可重复性的纯化和分离技术的投资正在降低批间差异，提高安全性，并使製造商能够更稳定地满足严格的监管要求。同时，人们越来越关注能够缩短生产週期并提高应对需求激增应对力的替代平台和製程强化策略。

检验美国新关税和贸易合规变化如何促使供应链重组、采购转移和采购调整。

2025年实施的政策变化和贸易措施给包括狂犬病免疫球蛋白在内的生物治疗药物的全球供应商和下游采购商带来了新的成本和运营方面的考虑。不断增加的关税压力和相关的合规要求提高了进口零件和成品的到岸成本，迫使供应链管理者重新评估其筹资策略和物流运作。为此，生产商和经销商正在探索近岸外包、供应商多元化以及库存管理方式的调整，以应对额外的财务和管理负担。

确定产品类型、分销管道、最终用户环境和给药途径如何共同决定可访问性、安全考虑因素和操作复杂性

了解产品细分的细微差别有助于理解治疗属性和分销管道如何相互作用，从而决定临床应用和营运的复杂性。根据类型，免疫球蛋白可分为马源性和人源性，二者在临床、安全性和生产方面各有其独特的考量，这些考虑会影响采购选择和临床医生的偏好。由于生产规模化，马源性产品在某些情况下通常具有更广泛的可用性，而人源性产品在许多司法管辖区更符合安全性认知和监管要求。

绘製出各区域独特的优先事项和结构性限制因素图，这些因素决定了狂犬病免疫球蛋白在全球的取得、采购和分发方式。

区域动态对美洲、欧洲、中东和非洲以及亚太地区的临床用药途径、采购标准和监管预期有显着影响，每个区域都有其独特的优先事项和结构性限制。美洲通常集中拥有先进的低温运输物流和一体化的医院采购系统，能够保障都市区及时获得医疗服务，而农村和偏远社区则必须依赖有针对性的公共卫生干预措施。区域特征也凸显了影响处方笺决策的严格法律规范和支付方参与模式。

分析製造商、经销商和医疗保健提供者之间不断演变的竞争和合作模式，这些模式会影响供应链的连续性和分销网路的覆盖范围。

随着相关人员积极应对临床需求模式、监管要求以及对供应韧性的迫切需求，製造商、经销商和临床供应商之间的竞争动态正在改变。成熟的马源和人源免疫球蛋白生产商在生技药品生产和监管申报方面拥有深厚的专业知识，并经常投资于製程改进，以提高安全性、均一性和产量。同时，新兴参与企业和契约製造拥有製程强化和灵活的灌装密封服务等能力，可以帮助缩短前置作业时间并实现本地化供应。

製造商、经销商和医疗保健系统可采取的实际步骤，以增强免疫球蛋白疗法的供应韧性、临床可及性和监管准备。

产业领导者可以采取有针对性的措施，增强供应链韧性，改善临床应用，并使商业策略与公共卫生优先事项保持一致。首先，投资多元化的製造地，并对关键原料和填充包装服务进行二次认证，可以降低单点故障的风险，并能更灵活地应对需求波动。此外，提高库存可视性，并在整个分销网路中部署先进的温度监控系统，可以减少废弃物，并增强临床用户的信心。

一种多方面的调查方法，结合了专家访谈、监管审查和业务流程分析，以产生实际且检验的见解。

本研究采用系统性的多方法研究方法，整合了访谈、监管文件分析和业务流程审查，以确保为洞察和建议奠定坚实的基础。透过与临床医生、供应链经理、采购负责人和生产专家进行深入访谈，收集一手数据，以了解他们对临床实践、分销挑战和生产能力的实际观点。将这些定性数据与已发布的监管指南、临床建议和贸易政策文件进行三角验证，以检验发展趋势并检验新出现的挑战。

整合核心营运和临床要务，并确保价值链各环节协调一致，以保障狂犬病免疫球蛋白的供应和病患疗效。

总之，确保狂犬病免疫球蛋白的可靠供应需要采取协调一致的方法，涵盖生产创新、分销现代化和积极主动的筹资策略。及时给药的临床需求始终不变，而诸如来源多元化、提高低温运输可视性和临床医生培训等营运措施对于维持供应至关重要。贸易政策的变化和关税趋势的演变带来了额外的行政和成本方面的考量，各组织必须将这些因素纳入其合约、供应计划和风险管理框架中。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 狂犬病免疫球蛋白市场（按类型划分）

  • 马
  • 人类

9. 狂犬病免疫球蛋白市场依给药途径划分

  • 浸润
  • 肌肉内注射

第十章 狂犬病免疫球蛋白市场（依通路划分）

  • 离线
  • 在线的

第十一章 狂犬病免疫球蛋白市场（以最终用户划分）

  • 诊所
    • 政府诊所
    • 私人诊所
  • 医院
    • 私立医院
    • 公立医院

12. 狂犬病免疫球蛋白市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 狂犬病免疫球蛋白市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国狂犬病免疫球蛋白市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国狂犬病免疫球蛋白市场

17. 中国的狂犬病免疫球蛋白市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bavarian Nordic A/S
  • Bayer AG
  • Bharat Serums and Vaccines Limited
  • Bio-Med Private Limited
  • BIoTest AG
  • Cadila Pharmaceuticals Limited
  • China Biologic Products Holdings, Inc.
  • CSL Behring LLC
  • GlaxoSmithKline plc
  • Grifols, SA
  • Hualan Biological Engineering, Inc.
  • Indian Immunologicals Limited
  • Kamada Ltd.
  • Kedrion Biopharma SpA
  • Octapharma AG
  • Sanofi Pasteur SA
  • Serum Institute of India Pvt. Ltd.
  • Shuanglin Bio-pharmaceutical Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Vins Bio Products Limited
Product Code: MRR-7A380DA7C465

The Rabies Immunoglobulins Market was valued at USD 802.15 million in 2025 and is projected to grow to USD 856.20 million in 2026, with a CAGR of 8.11%, reaching USD 1,385.47 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 802.15 million
Estimated Year [2026] USD 856.20 million
Forecast Year [2032] USD 1,385.47 million
CAGR (%) 8.11%

Establishing the clinical and operational context for rabies immunoglobulin access, supply chain priorities, and stakeholder imperatives in modern healthcare delivery

Rabies remains a critical public health priority where timely administration of immunoglobulins can be lifesaving, and the landscape for these therapeutics is shaped by clinical urgency, evolving production paradigms, and regulatory scrutiny. This introduction frames the clinical role of rabies immunoglobulins in post-exposure prophylaxis and outlines the principal supply chain, manufacturing, and clinical adoption dynamics that stakeholders must navigate. It also highlights intersections between clinical practice patterns and distribution channels that influence patient access.

Clinicians rely on immunoglobulins to provide immediate passive immunity while active vaccination elicits a protective response. Consequently, supply continuity, cold chain integrity, and appropriate clinical training represent practical imperatives. From a manufacturing perspective, production platforms for equine and human immunoglobulins differ in complexity and regulatory expectations, and these differences drive strategic choices for producers and health systems. Meanwhile, distribution frameworks spanning hospital and retail channels determine point-of-care availability and influence procurement strategies.

Transitioning from clinical fundamentals to operational considerations, the subsequent sections explore how market drivers, tariff implications, segmentation nuances, regional demand patterns, competitive dynamics, and recommended actions converge to shape near-term priorities for manufacturers, payers, and public health authorities.

How manufacturing innovation, procurement modernization, and regulatory emphasis are reshaping rabies immunoglobulin availability, resilience, and clinical practice

The rabies immunoglobulin landscape is experiencing transformative shifts driven by advances in biological manufacturing, changing procurement practices within health systems, and evolving expectations for equitable access. On the manufacturing front, investments in more scalable and reproducible purification and fractionation technologies are reducing lot-to-lot variability and improving safety profiles, enabling manufacturers to meet stringent regulatory requirements more consistently. Concurrently, there is growing interest in alternative platforms and process intensification strategies that can shorten production cycles and improve responsiveness to demand surges.

Procurement strategies are also shifting from transactional purchases toward integrated supply resilience planning, with hospitals and national programs favoring multi-sourcing arrangements and strategic stockpiling to mitigate disruptions. Digital tools for inventory management and temperature monitoring are increasingly integrated across distribution networks to reduce wastage and enhance traceability. In parallel, clinical practice is adapting as clinicians and public health practitioners emphasize timely administration and standardized protocols, supported by updated clinical guidance and training initiatives.

These shifts are further influenced by heightened regulatory attention to biologic safety and evolving reimbursement frameworks that aim to balance affordability with manufacturer sustainability. Taken together, these transformative forces are reshaping how products are developed, stocked, and administered, and they underscore the need for coordinated action across public and private stakeholders to preserve patient access and maintain high standards of care.

Examining how new tariff measures and trade compliance changes in the United States have prompted supply chain realignment, sourcing shifts, and procurement adaptation

Policy changes and trade instruments enacted in the United States during 2025 have introduced new cost and operational considerations for global suppliers and downstream purchasers of biologic therapeutics, including rabies immunoglobulins. Increased tariff pressures and associated compliance requirements have elevated landed costs for imported components and finished products, prompting supply chain managers to reassess sourcing strategies and logistics arrangements. In response, producers and distributors have explored nearshoring, supplier diversification, and changes in inventory policies to manage added financial and administrative burdens.

These tariff dynamics have also affected decisions around manufacturing footprint and procurement timing. Manufacturers that rely on cross-border flows for raw materials or fill-finish activities have faced added complexity in cost modeling and contractual negotiations. Health systems and public procurement entities have become more vigilant in scrutinizing total landed costs and delivery timeframes, which in some instances has lengthened lead times for contractual awards and prompted contingency arrangements to secure essential immunoglobulin stocks.

Importantly, regulatory compliance and customs documentation requirements introduced alongside tariff changes have increased administrative workload for suppliers and distributors, necessitating investment in customs expertise and trade compliance systems. While these shifts have not altered the clinical rationale for immunoglobulin administration, they have elevated the operational priority of supply chain visibility and contractual flexibility for organizations responsible for ensuring patient access.

Clarifying how type, distribution pathways, end user settings, and administration routes collectively define access, safety considerations, and operational complexity

A nuanced understanding of product segmentation clarifies how therapeutic characteristics and distribution pathways interact to determine clinical access and operational complexity. Based on type, the landscape differentiates between equine-derived immunoglobulins and human-derived immunoglobulins, each presenting distinct clinical, safety, and manufacturing considerations that inform procurement choices and clinician preferences. Equine products often offer broader availability in certain settings due to production scalability, while human products align closely with safety perceptions and regulatory expectations in many jurisdictions.

Based on distribution channel, availability is shaped across hospital pharmacy, online pharmacy, and retail pharmacy avenues. Hospital pharmacy pathways further delineate into private hospital pharmacy and public hospital pharmacy contexts, which diverge in procurement protocols, budget cycles, and stocking policies. Retail pharmacy distribution similarly splits into chain retail pharmacy and independent retail pharmacy operations, each with differing inventory management capabilities and ties to community healthcare providers. Online pharmacy models add another layer of complexity with remote ordering and logistics considerations that affect turn-around time and temperature-sensitive handling.

Based on end user, clinical delivery occurs through clinics and hospitals. Clinics are further categorized into government clinics and private clinics, reflecting divergent funding mechanisms, referral pathways, and formulary processes. Hospitals are similarly viewed through the lenses of private hospitals and public hospitals, where differences in purchasing power, tendering procedures, and emergency preparedness influence access. Finally, based on route of administration, practices typically follow infiltration or intramuscular approaches, with clinical guidance and training shaping route selection and administration protocols. Integrating these segmentation dimensions provides a practical framework for aligning manufacturing capacity, distribution strategies, and clinical education to improve patient access.

Mapping distinct regional priorities and structural constraints that determine how rabies immunoglobulins are accessed, procured, and distributed across global regions

Regional dynamics exert a powerful influence on clinical access, procurement norms, and regulatory expectations across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region displaying unique priorities and structural constraints. The Americas generally show a concentration of advanced cold chain logistics and integrated hospital procurement systems, which supports timely access in urban centers but leaves rural and remote communities reliant on targeted public health interventions. This regional profile also emphasizes stringent regulatory oversight and payer engagement models that shape formulary decisions.

Europe, Middle East & Africa encompasses a broad spectrum of healthcare system maturity, from highly centralized public procurement programs to fragmented private provider networks. In many countries, the priority is on equitable distribution and integration with primary care vaccination campaigns, while regulatory harmonization efforts aim to streamline approvals and pharmacovigilance. The Middle East component often features centralized procurement for public health programs, whereas parts of Africa contend with logistical hurdles and cold chain gaps that require donor and multilateral support.

Asia-Pacific presents diverse market structures with high-capacity manufacturing hubs in some countries and rapidly expanding healthcare access in others. National immunization priorities and local production capabilities influence procurement choices, and regional trade agreements can facilitate cross-border supply flows. Across all regions, public health priorities, infrastructure investments, and regulatory alignment determine how effectively rabies immunoglobulins reach patients in need.

Analyzing evolving competitive and partnership models among manufacturers, distributors, and healthcare providers that influence supply continuity and channel reach

Competitive dynamics among manufacturers, distributors, and clinical suppliers are evolving as stakeholders respond to clinical demand patterns, regulatory requirements, and supply resilience imperatives. Established producers of equine and human immunoglobulins maintain deep expertise in biologic production and regulatory submissions, and they often invest in process improvements to enhance safety, consistency, and yield. At the same time, emerging entrants and contract manufacturers bring capabilities in process intensification and flexible fill-finish services that can reduce lead times and support localized supply arrangements.

Distributors and hospital group purchasing organizations play an influential role in channel availability, leveraging scale to negotiate supply agreements and coordinate cold chain logistics. Pharmacy networks, both retail and online, are adapting inventory management and last-mile delivery processes to accommodate the temperature sensitivity of immunoglobulin therapies and to meet clinician expectations for timely access. Partnerships between manufacturers and national health programs or international agencies also influence distribution pathways, particularly where public health campaigns or outbreak responses necessitate coordinated logistics.

Across the value chain, strategic collaboration-whether through toll manufacturing agreements, joint procurement initiatives, or distribution partnerships-serves as a practical mechanism for spreading risk and improving responsiveness. These collaborative models are increasingly important as stakeholders seek to ensure continuity of supply while managing the administrative and cost implications introduced by recent trade and regulatory developments.

Actionable steps for manufacturers, distributors, and healthcare systems to enhance supply resilience, clinical access, and regulatory alignment for immunoglobulin therapies

Industry leaders can pursue targeted actions to strengthen supply resilience, improve clinical access, and align commercial strategies with public health priorities. First, investing in diversified manufacturing footprints and qualifying secondary sources for critical raw materials and fill-finish services helps to reduce single-point vulnerabilities and enables more agile responses to demand fluctuations. Complementary to this, enhancing inventory visibility across distribution networks and implementing advanced temperature-monitoring systems will reduce wastage and improve trust among clinical users.

Second, building stronger collaborations with hospital pharmacy networks, public procurement agencies, and clinic systems enables better alignment between production planning and clinical demand. These collaborations should include capacity-building initiatives that uplift clinical training on administration routes and handling protocols, which in turn helps to standardize practice and improve patient outcomes. Third, commercial teams should re-evaluate contracting terms to incorporate flexibility for tariff-related cost shifts and to embed contingency clauses that safeguard supply under changing trade regimes.

Finally, prioritizing data-driven regulatory engagement and pharmacovigilance cooperation can accelerate approvals for process improvements while maintaining safety standards. Together, these actions create a holistic approach that balances operational resilience, clinical reliability, and commercial viability while ensuring that patient access remains the central objective.

Description of the multi-method research approach combining expert interviews, regulatory review, and operational process analysis to produce actionable, validated insights

This research relies on a systematic, multi-method approach that integrates primary interviews, regulatory document analysis, and operational process reviews to ensure a robust foundation for insights and recommendations. Primary inputs were gathered through in-depth conversations with clinicians, supply chain leaders, procurement officers, and manufacturing specialists to capture actionable perspectives on clinical practice, distribution challenges, and production capabilities. These qualitative inputs were triangulated with publicly available regulatory guidance, clinical recommendations, and trade policy documents to validate trends and identify emergent issues.

Operational process reviews examined production pathways for equine and human immunoglobulins, distribution workflows across hospital and retail channels, and administration protocols in clinics and hospitals. Attention was paid to regulatory submission pathways, cold chain requirements, and the implications of tariff and trade compliance changes on cross-border logistics. Where applicable, case studies and anonymized procurement scenarios illustrated how organizations have adapted contracting and inventory strategies to maintain access during supply fluctuations.

Finally, findings were synthesized into actionable recommendations through iterative expert validation, ensuring that conclusions are grounded in practitioner experience and current policy frameworks. The methodology emphasizes transparency and traceability so stakeholders can understand the evidentiary basis for strategic guidance and apply it to operational planning and clinical program design.

Synthesis of core operational and clinical imperatives that must be coordinated across the value chain to preserve access and patient outcomes for rabies immunoglobulins

In conclusion, ensuring reliable access to rabies immunoglobulins requires a coordinated approach that spans manufacturing innovation, distribution modernization, and proactive procurement strategies. Clinical imperatives for timely administration remain unchanged, and operational measures such as diversified sourcing, enhanced cold chain visibility, and clinician training are essential to preserve access. Trade policy shifts and tariff developments have introduced additional administrative and cost considerations that organizations must integrate into contracting, supply planning, and risk management frameworks.

Regional differences in regulatory environments, healthcare infrastructure, and procurement practices necessitate tailored approaches that respect local priorities and logistical realities. Segmentation by product type, distribution channel, end user, and administration route provides a pragmatic lens for aligning production capacity with clinical need. Strategic collaboration across the value chain-whether through contracting arrangements, distribution partnerships, or capacity-building initiatives-can mitigate risk and improve responsiveness.

Moving forward, stakeholders who invest in supply resilience, regulatory engagement, and clinician education will be best positioned to safeguard patient outcomes and operational continuity. The recommendations presented here are intended to support evidence-informed decisions that balance safety, access, and commercial sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Rabies Immunoglobulins Market, by Type

  • 8.1. Equine
  • 8.2. Human

9. Rabies Immunoglobulins Market, by Route Of Administration

  • 9.1. Infiltration
  • 9.2. Intramuscular

10. Rabies Immunoglobulins Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Rabies Immunoglobulins Market, by End User

  • 11.1. Clinics
    • 11.1.1. Government Clinics
    • 11.1.2. Private Clinics
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals

12. Rabies Immunoglobulins Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Rabies Immunoglobulins Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Rabies Immunoglobulins Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Rabies Immunoglobulins Market

16. China Rabies Immunoglobulins Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bavarian Nordic A/S
  • 17.6. Bayer AG
  • 17.7. Bharat Serums and Vaccines Limited
  • 17.8. Bio-Med Private Limited
  • 17.9. Biotest AG
  • 17.10. Cadila Pharmaceuticals Limited
  • 17.11. China Biologic Products Holdings, Inc.
  • 17.12. CSL Behring LLC
  • 17.13. GlaxoSmithKline plc
  • 17.14. Grifols, S.A.
  • 17.15. Hualan Biological Engineering, Inc.
  • 17.16. Indian Immunologicals Limited
  • 17.17. Kamada Ltd.
  • 17.18. Kedrion Biopharma S.p.A.
  • 17.19. Octapharma AG
  • 17.20. Sanofi Pasteur SA
  • 17.21. Serum Institute of India Pvt. Ltd.
  • 17.22. Shuanglin Bio-pharmaceutical Co., Ltd.
  • 17.23. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • 17.24. Vins Bio Products Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RABIES IMMUNOGLOBULINS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RABIES IMMUNOGLOBULINS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA RABIES IMMUNOGLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY EQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY EQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY GOVERNMENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY GOVERNMENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY GOVERNMENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 109. GCC RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GCC RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. GCC RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. GCC RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. GCC RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 115. GCC RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 130. G7 RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. G7 RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. G7 RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. G7 RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. G7 RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 136. G7 RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 137. NATO RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. NATO RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. NATO RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. NATO RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. NATO RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. NATO RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 143. NATO RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA RABIES IMMUNOGLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)